Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,020 articles
Exclusive: Expert Weighs In On Why Orbital Datacenters Could Likely Work In Tandem With Ground-Based AI Infrastructure
Space-based AI compute has been positioned by the tech industry as a solution to several challenges facing current Earth-based datacenter...
Wheaton Precious Metals Corp. (NYSE:WPM) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Wheaton Precious Metals Corp. (NYSE:WPM – Get Free Report) have earned an average recommendation of “Moderate Buy” from...
Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Time to Buy?
Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had...
Phreesia (NYSE:PHR) Shares Gap Up – Time to Buy?
Shares of Phreesia, Inc. (NYSE:PHR – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $11.77,...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up – Time to Buy?
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up before the market opened on Friday . The stock had...
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year High – Still a Buy?
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report)’s share price reached a new 52-week high on Friday . The company traded as...
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
Biohaven Ltd. (NYSE:BHVN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seventeen brokerages...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have received a consensus rating of “Moderate Buy” from the...
McKesson Corporation (NYSE:MCK) Receives Consensus Recommendation of “Moderate Buy” from Analysts
McKesson Corporation (NYSE:MCK – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seventeen ratings...
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy” by Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine...
📰
2 Defensive Healthcare Stocks to Buy Right Now
These two stocks make fantastic long-term holdings.
📰
2 Defensive Healthcare Stocks to Buy Right Now
These two stocks make fantastic long-term holdings.
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of ProKidney Corp. (NASDAQ:PROK – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings...
AdaptHealth Corp. (NASDAQ:AHCO) Receives Consensus Rating of “Moderate Buy” from Analysts
AdaptHealth Corp. (NASDAQ:AHCO – Get Free Report) has been given an average rating of “Moderate Buy” by the six analysts that are...
The Pennant Group, Inc. (NASDAQ:PNTG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of The Pennant Group, Inc. (NASDAQ:PNTG – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy”...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have received a consensus recommendation of “Moderate Buy” from...
Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High – Should You Buy?
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as...
Oxford BioDynamics (LON:OBD) Stock Price Up 11.1% – Time to Buy?
Oxford BioDynamics Plc (LON:OBD – Get Free Report) shares traded up 11.1% during mid-day trading on Friday . The stock traded as high as GBX...
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded...
Sanofi (NASDAQ:SNY) Upgraded at Sanford C. Bernstein
Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY – Free Report) to a strong-buy rating in a research report sent to investors on...
Citigroup Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target boosted by Citigroup from $120.00 to $125.00 in a report issued on...
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery...
📰
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
📰
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
📰
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
📰
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
📰
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
📰
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
📰
1 High-Yield Dividend Stock That's Too Cheap to Ignore
Sometimes "boring" is the way to go.
Foguth Wealth Management LLC. Makes New $734,000 Investment in Eli Lilly and Company $LLY
Foguth Wealth Management LLC. bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according...
Foguth Wealth Management LLC. Makes New $734,000 Investment in Eli Lilly and Company $LLY
Foguth Wealth Management LLC. bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according...
Foguth Wealth Management LLC. Makes New $734,000 Investment in Eli Lilly and Company $LLY
Foguth Wealth Management LLC. bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according...
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company $LLY
GAMMA Investing LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 27.0% in the fourth quarter, according to its...
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company $LLY
GAMMA Investing LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 27.0% in the fourth quarter, according to its...
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company $LLY
GAMMA Investing LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 27.0% in the fourth quarter, according to its...
City Center Advisors LLC Makes New $462,000 Investment in Johnson & Johnson $JNJ
City Center Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ – Free Report) in the 4th quarter, according to its most...
City Center Advisors LLC Makes New $462,000 Investment in Johnson & Johnson $JNJ
City Center Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ – Free Report) in the 4th quarter, according to its most...
City Center Advisors LLC Makes New $462,000 Investment in Johnson & Johnson $JNJ
City Center Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ – Free Report) in the 4th quarter, according to its most...
📰
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.
📰
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven...
📰
This Hims & Hers Move Could Destroy Competitors
The Wegovy pill could change Hims & Hers' growth in 2026.